<DOC>
	<DOCNO>NCT00438568</DOCNO>
	<brief_summary>The purpose study find insulin , administer `` nasal spray '' nasal passage , improve memory adult mild cognitive impairment ( MCI ) Alzheimer 's disease .</brief_summary>
	<brief_title>SNIFF 120 : Study Nasal Insulin Fight Forgetfulness ( 120 Days )</brief_title>
	<detailed_description>A grow body evidence suggest insulin play role normal memory process insulin abnormality may contribute cognitive brain change associate Alzheimer 's disease ( AD ) . Interestingly , insulin administer nasal cavity transport within minute brain , affect blood sugar insulin level . This study consist randomize double-blind , placebo-controlled parallel group trial 90 participant AD MCI receive daily intranasal administration either insulin ( 10 20 IU twice day total dose 20 40 IU per day ) placebo ( saline twice day ) 4 month . The study examine effect intranasal insulin administration cognition , cerebral glucose metabolism , β-amyloid ( Aβ ) cerebrospinal fluid ( CSF ) plasma , test hypothesis daily intranasal insulin administration 4 month facilitate memory adult AD , adult mild cognitive impairment ( MCI ) . A subset participant option participate 2 sub-studies : PET scan ( prior end treatment ) determine whether intranasal insulin increase cerebral glucose metabolism ; lumbar puncture ( LPs ) end treatment determine effect intranasal insulin administration CSF Aβ level .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Age 55 great Good physical health Memory impairment diagnosis mild cognitive impairment ( MCI ) Alzheimer 's disease ( AD ) Participants stable dos Memantine ( Namenda ) cholinesterase inhibitor eligible Chronic sinus problems/allergies chronic use nasal decongestant antihistamine Significant neurologic disease might affect cognition ( AD ) , stroke , Parkinson 's disease , multiple sclerosis , severe head injury loss consciousness 30 minute permanent neurologic symptom Significant medical illness organ failure , uncontrolled hypertension cardiovascular disease , chronic obstructive pulmonary disease , liver disease , kidney disease Preexisting diabetes current previous use hypoglycemic agent insulin ; participant exclude fast blood sugar great 165 baseline OGTT Clinically significant elevation liver function test , cholesterol , triglyceride Major psychiatric disorder ( e.g. , untreated major depression schizophrenia ) Chronic use follow type medication : antipsychotic , anxiolytic , opiate</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>amyloid protein</keyword>
	<keyword>brain metabolism</keyword>
	<keyword>glucose metabolism</keyword>
	<keyword>insulin sensitivity /resistance</keyword>
	<keyword>cognition disorder</keyword>
</DOC>